International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.342 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
PURPOSE: To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. METHODS: A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. RESULTS: Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. CONCLUSION: These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Journal of Clinical Oncology
- Topic
- Multiple Myeloma Research and Treatments
- Field
- Medicine
- Canadian institutions
- —
- Funders
- CilagOnyx PharmaceuticalsNational University Health SystemNagoya City UniversityGil Medical Center, Gachon UniversityGenentechSahlgrenska UniversitetssjukhusetUniversità degli Studi di PaviaKeio UniversityCedars-Sinai Medical CenterWeill Cornell Medical CollegeAbbott LaboratoriesQueen Mary University of LondonUniversity of PittsburghAnkara UniversitesiUniversity of Arkansas for Medical SciencesArray BioPharmaTel Aviv UniversityGachon UniversityYork UniversityNorthwestern UniversityEmory UniversityAmerican Society of Clinical OncologyUniversität WienCelgeneDaiichi Sankyo EuropeNational Cancer InstituteGilead SciencesNational and Kapodistrian University of AthensKarolinska InstitutetMemorial Sloan-Kettering Cancer CenterBristol-Myers SquibbDaiichi-SankyoTakeda OncologyMassachusetts General HospitalSanofiAmgen
- Keywords
- MedicineMultiple myelomaIntensive care medicineTransplantationAdverse effectLenalidomideDiseaseAnemiaAutologous stem-cell transplantationConcomitantInternal medicineSurgery
- Has abstract in OpenAlex
- yes